The results of a 24 month controlled, prospective study of relapsing MS patients at risk for PML who switched from long term natalizumab to teriflunomide

Authors

• Stanley Cohan, Providence Multiple Sclerosis Center, USA.Follow
• Kyle E Smoot, Providence Multiple Sclerosis Center, Providence Brain and Spine Institute, USAFollow
• Kiren Kresa-Reahl, Providence Multiple Sclerosis Center, USA.Follow
• Chiayi Chen, Providence Multiple Sclerosis Center, Providence Brain and Spine Institute, USAFollow
• Tiffany Gervasi-Follmar, Providence Multiple Sclerosis Center, Providence Brain and Spine Institute, USAFollow

Document Type

Presentation

Publication Date

2018

Keywords

oregon; providence neuroscience institute

Area of Special Interest

Neurosciences (Brain & Spine)

Specialty/Research Institute

Neurosciences